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Synaptic declineSynaptic pathology in Alzheimer's disease brains is thought to involve soluble Aβ42 peptide. Here, sterile in-
cubation in PBS caused small Aβ42 oligomer formation as well as heterogeneous, 6E10-immunopositive ag-
gregates of 80–100 kDa. The high molecular weight aggregates (H-agg) formed in a time-dependent manner
over an extended 30-day period. Interestingly, an inverse relationship between dimeric and H-agg formation
was more evident when incubations were performed at 37 °C as compared to 23 °C, thus providing an exper-
imental strategy with which to address synaptic compromise produced by the different Aβ aggregates. H-agg
species formed faster and to higher levels at 37 °C compared to 23 °C, and the two aggregate preparations
were evaluated in hippocampal slice cultures, a sensitive system for monitoring synaptic integrity. Applied
daily at 80–600 nM for 7 days, the Aβ42 preparations caused dose-dependent and aggregation-dependent
declines in α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) and N-methyl-D-aspartate
(NMDA) receptor subunits as well as in presynaptic components. Unlike the synaptic effects, Aβ42 induced
only trace cellular degeneration that was CA1 speciﬁc. The 37 °C preparation was less effective at decreasing
synaptic markers, corresponding with its reduced levels of Aβ42 monomers and dimers. Aβ42 dimers
decayed signiﬁcantly faster at 37 °C than 23 °C, and more rapidly than monomers at either temperature.
These ﬁndings indicate that Aβ42 can self-aggregate into potent synaptotoxic oligomers as well as into larger
aggregates that may serve to neutralize the toxic formations. These results will add to the growing debate
concerning whether high molecular weight Aβ complexes that form amyloid plaques are protective through
the sequestration of oligomeric species.h and Training Center, 115
ke, Pembroke, NC 28372-1510,
. Wisniewski).
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is an age-related neurodegenerative dis-
order characterized by progressive cognitive decline, motor function
impairment, and behavioral changes [1]. Multifarious investigations
into the causative agent of AD have led to the amyloid cascade hy-
pothesis, implicating the amyloid-β peptide (Aβ) as a major causative
factor in AD pathogenesis. Aβ is predominately a 38-, 40-, or 42-
amino acid peptide derived through differential cleavage of the amy-
loid precursor protein (APP) by β- and γ-secretases [2,3]. Increased
amounts of Aβ42 have been associated with AD [4] and this peptide
has shown a greater propensity to oligomerize in vitro [5,6]. Several
mutations in the genes encoding APP or subunits of the secretases
that promote production of Aβ42 have been linked to familial
AD [7–12]. Furthermore, transgenic mice expressing mutated
APP and/or secretase proteins display memory deﬁcits associatedwith increased levels of total Aβ, increased Aβ42/Aβ40 ratio, and
intraneuronal Aβ aggregation [13–16]. These discoveries provide
strong evidence that Aβ is a critical component of AD-associated
brain defects.
Several forms of Aβ have been implicated in AD pathology. Post-
mortem comparison of brain extracts from AD patients to normal in-
dividuals shows a close correlation between increased levels of
soluble Aβ and neurodegeneration [17–19]. Additionally, intraneuro-
nal Aβ42 was detected postmortem in patients with impaired cogni-
tion [20]. In further studies, attempts were made to isolate the
neurotoxic form of Aβ. Extracts from AD brains yielded Aβ42 aggre-
gates with molecular weights from 10 kDa to over 100 kDa [4],
whereas another group predominantly found lower molecular weight
Aβ oligomers including monomers, dimers, and trimers [17]. In a
proof-of-concept study, soluble Aβ dimers isolated from AD brains
produced memory impairments in wild-type rats, and also disrupted
signaling in vitro [21]. Similarly, Lesné et al. [22] isolated a speciﬁc
56 kDa soluble Aβ oligomer that was detected at the onset of memory
deﬁcits in a transgenic mouse model of AD and caused spatial memo-
ry impairment when inoculated into wild-type rats. These studies
reafﬁrm a pathological role for Aβ oligomers; however, the species
and the exact role in neurodegeneration remain elusive.
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synthetic peptide preparations have become widely used to investi-
gate oligomerization events. Initial studies determined that solutions
which are allowed to age for several days become neurotoxic. Analy-
sis revealed that the aged solutions contain highmolecular weight ag-
gregates of Aβ as opposed to the predominate monomeric species
found in freshly prepared solutions [23]. Several different soluble
oligomers of synthetic Aβ have been described, ranging from dimers
to 24mers [17,24], including a soluble dodecamer unique to Aβ42
with a molecular weight of 55.2 kDa [25]. Also, toxicity of the synthet-
ic peptide has been shown as Aβ42 causes neuronal damage and pre-
cludes glutamatergic signaling in neuronal cultures [26–28]. Although
neuronal cultures have been widely used to study neurotoxicity,
organotypic hippocampal slice cultures provide a convenient in vitro
model that more closely maintains the structure and neuronal con-
nections of the mature hippocampus [29]. Furthermore, this model
is useful in studying Aβ-induced pathology since neurons in the hip-
pocampal slice cultures internalize exogenous Aβ42 leading to de-
cline of the presynaptic marker, synaptophysin [30,31]. In the
present study, we utilized hippocampal slice cultures to determine
the effect of pre-aggregated Aβ42 solutions on synaptic integrity.
Our data demonstrate that synaptic decline induced by Aβ42 solu-
tions is affected by the conditions under which peptide aggregation
occurs.
2. Materials and methods
2.1. Aβ aggregation
Aβ42, a gift from Professor Charles Glabe (University of California,
Irvine, CA), and Aβ40 (Bachem, King of Prussia, PA) were reconsti-
tuted to 2.22 mM in 0.1 M NaOH and then bath sonicated at room
temperature for 1 min. The solutions were diluted to 45 μM in 0.1 M
PBS, immediately sterile ﬁltered, and allowed to aggregate in the
dark at 37 °C or 23 °C for 0–30 d. Aliquots of the solutions were either
prepared for electrophoresis or stored at−80 °C. Experiments utiliz-
ing Aβ42 obtained from American Peptide Company, Inc. (Sunnyvale,
CA) yielded similar results.
2.2. Organotypic hippocampal slice cultures
Brain tissue from postnatal day twelve Sprague–Dawley rats
(Charles River Laboratories, Wilmington, MA) was rapidly removed
to prepare slices as described [29,32–35]. Transverse slices of hippo-
campus (400 μm) were quickly prepared and placed on insert mem-
branes (Millipore Corporation, Billerica, MA) with cultured medium
consisting of 50% basal medium Eagle (Sigma, St. Louis, MO), 25% Ear-
le's balanced salts (Sigma), 25% horse serum (Gemini Bio-products,
Sacramento, CA), and deﬁned supplements, as described previously
[29,32–35]. Slices were maintained at 37 °C in 5% CO2-enriched atmo-
sphere for 14–25 d before experimental use and were maintained in
culture for the same length of time throughout the experiment by
staggering treatments. For Aβ42 treatments, pre-aggregated or fresh
solutions were further diluted in serum free media and applied brieﬂy
to the surface of the tissue and then placed in the bottom of the well
containing the insert for 8–12 h. Then media containing serum were
added for 12 h before the application was repeated. For immunoblot-
ting, cultured slices were harvested with a soft brush and sonicated in
sets of 6–8 slices using ice-cold homogenization buffer, then protein
content was determined using Pierce BCA Protein Assay (Thermo Sci-
entiﬁc, Rockford, IL) with similar results obtained with Dc Protein
Assay (Bio-Rad, Hercules, CA). All of the studies were carried out in
strict accordance with the recommendations from the Guide for the
Care and Use of Laboratory Animals from the National Institutes of
Health. Animal use was conducted in accordance with an approvedprotocol from the Institutional Animal Care and Use Committee of
the University of North Carolina – Pembroke.
2.3. Immunoblot analysis
Equal protein aliquots (80 μg) of the slice samples were denatured
in SDS buffer for 5 min at 100 °C, then separated by 4–15% tris-glycine
SDS-PAGE (BioRad) and blotted to nitrocellulose (BioRad). Alterna-
tively, aliquots (1 μg) of the Aβ solutions were mixed with SDS buffer,
incubated at 40 °C for 30 min, cooled to room temperature, separated
on 16.5% tris-tricine or 4–20% tris-glycine SDS-PAGE (BioRad), and
then transferred to nitrocellulose. For dot blots, samples in 0.15%
SDS were treated as above and equal amount protein blotted onto ni-
trocellulose and allowed to dry. The blots were stained for different
markers using the following antibodies: calpain-mediated breakdown
product (BDP, as previously described [29,36]), GluR1 prepared as
previously described [37], GluR2 (1:250; Millipore), NR1 (selective
for splice variants NR1-1a, NR1-1b, NR1-2a, NR1-2b; 1:100; Milli-
pore), NR2A (1:100; Millipore), NR2B (1:75; Millipore), synaptophy-
sin (1:100; Millipore), synapsin II (1:600; Calbiochem, La Jolla, CA),
actin (1:250; Sigma), 6E10 against amino acids 1–16 of Aβ (1:80; Cov-
ance, Emeryville, CA), 82E1 against amino acids 1–16 of Aβ (1:100, IBL,
Takasake-Shi, Japan), and A11 against amyloid oligomers (Professor
Charles Glabe, University of California, Irvine, CA). Secondary antibody
incubation utilized anti-IgG-alkaline phosphatase conjugates (1:1800,
BioRad), and color development used the 5-bromo-4-chloro-3-indolyl
phosphate and nitroblue tetrazolium substrate system. Development
of immunoreactivity was terminated before maximal intensity was
reached on the blots in order to avoid saturation and to ensure a linear
relationship with increasing amount of sample protein. Labeled bands
were scanned at high resolution to determine integrated optical den-
sity with BIOQUANT software (R & M Biometrics, Nashville, Tennes-
see). The immunostaining of glutamate receptor subunits and other
proteins on blots was routinely tested for linearity within the optical
density range exhibited in cultured slice samples. Tests were con-
ducted by immunoblotting sets of samples containing 2–100 μg pro-
tein from a single tissue preparation. Typical immunoreactivity plots
exhibited linear relationships often across N10-fold span of staining
intensity and with a high correlation coefﬁcient (r=0.95–0.99). The
speciﬁc immunoreactivity of samples across immunoblots was com-
bined by normalizing against the mean measures of common sample
groups present in the different blots.
2.4. Histology
Hippocampal slice cultures were maintained until culture day 25
and treated with Aβ42 as described above (Section 2.2). Twenty-
four hours after the last Aβ42 treatment, media were replaced with
serum-free media containing 10 μg/ml of propidium iodide (PI;
Fluka, St. Louis, MO) for 1 h. Excitotoxicity was induced in cultures
by maintaining them in media with 100 μM NMDA, 100 μM AMPA,
and 2 mM excess CaCl2 for 24 h prior to PI staining. Slices were then
ﬁxed in 4% paraformaldehyde for 4 h at 4 °C [38], rinsed in phosphate
buffer, mounted onto slides, and dried. After imaging for PI, whole
mounts were Nissl stained. Alternatively, ﬁxed slices were sectioned
to 20 μm using a sliding microtome (Leica Microsystems, Nussloch,
Germany) equipped with a freezing stage (Physitemp Instruments,
Inc., Clifton, NJ). Immunohistochemistry was performed by BOND-
MAX (Leica) using GluR1 primary antibody [37] and Bond Polymer
Reﬁne Detection kit (Leica). A Nikon AZ100 Microscope equipped
with AZ-FL Epi-ﬂuorescence, Fiber Illuminator, AZ-Plan Fluor 5×
lense, and Q-Imaging QI Click camera (Nikon Instruments Inc., Mel-
ville, NY) was used for imaging. All images analyzed for PI staining
received the same gain, exposure time, intensity threshold, and
other measurement parameters that were capsulated within each
image ﬁle. Analysis was performed with NIS-Elements AR (Nikon):
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tical density (sum density) at or above threshold, and area of staining
at or above threshold (binary area) was determined for all images.
2.5. Statistical analyses
Integrated optical densities for the various antigens and optical
density (sum density) or binary area of threshold PI staining were
expressed as mean±SEM. Statistical signiﬁcance was determined
by unpaired two-tailed t-tests, and one-way and two-way analyses
of variance (ANOVA), followed by the Tukey's multiple comparison
or Bonferroni's post hoc tests using GraphPad Prism version 3.00 for
Windows (GraphPad Software, San Diego, CA). Figures were prepared
for publication using Photoshop and Illustrator software (Adobe, San
Jose, CA).
3. Results
3.1. Formation of high molecular weight Aβ42 aggregates
In order to examine the extent of Aβ42 self-aggregation, 45 μM
Aβ42 in PBS was incubated at either 23 °C or 37 °C for 7 d, then sep-
arated by electrophoresis on a 16.5% tris-tricine gel. Immunoblotting
with 6E10 antibody indicated that while a fresh solution of Aβ42
was comprised of monomeric and dimeric species, Aβ42 incubated
at 23 °C showed these species in addition to higher molecular weight
aggregates (H-agg) ranging in size from 80 to 100 kDa (Fig. 1). Aβ42
incubated at 37 °C showed a decrease in the dimeric species and an
increase in H-agg species compared to the 23 °C solution. Primarily
monomeric peptide solubilized in hexaﬂuoroisopropanol was recon-
stituted in DMSO after speed-vac preparation, and found to exhibit
similar H-agg formation after 23 °C incubation in PBS (data not
shown). To obtain more information on the heterogeneity of the4.0
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Fig. 1. Aβ42 forms high molecular weight aggregates during long-term incubation in
PBS. Aliquots of Aβ42 (45 μM in PBS) were incubated in the dark for 7 days at 23 °C
or 37 °C. Loading buffer was then added to equal peptide amounts (1 μg), incubated
at 40 °C for 30 min, and separated by 16.5% tris-tricine SDS-PAGE alongside an
untreated control of non-aggregated Aβ42 (NT). Immunoblotting with 6E10 antibody
labeled Aβ42 monomer and dimer (arrows), as well as high molecular weight aggre-
gates (H-agg). The positions of 4- to 104-kDa standards are shown.H-agg species, Aβ42 solutions pre-aggregated at 37 °C were ana-
lyzed using a 4–20% tris-glycine gel, followed by 82E1 immunoblot-
ting (Fig. 2A). The heterogeneous H-agg spans 40 to 200 kDa in
this matrix and, as in Fig. 1, the molecular weight and band intensi-
ty increase over time. Relative integrated optical density of the
immunostaining showed a dramatic increase in H-agg during the
ﬁrst three days followed by a slower rate of increase, corresponding
with a steady decline in the oligomer of approximately 8 kDa
(Fig. 2B). Also in Fig. 2, Aβ40 does not aggregate into soluble high
molecular weight oligomers even after 14 days of incubation at
37 °C. This isoform of Aβ forms low molecular weight oligomers;
however some of this material remained at the top of the gel.
In order to further characterize the H-agg, unaggregated (0 d) and
pre-aggregated Aβ42 (30 d) preparations were subjected to low-49.2
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Fig. 2. Aβ42, but not Aβ40, forms high molecular weight aggregates when incubated at
37 °C. A. Aβ42 and Aβ40 (45 μM in PBS) were incubated for the indicated time (2–3 d
samples were pooled from 2 d and 3 d samples; 7–9 d were pooled from 7 d and 9 d
samples) or prepared from non-aggregated control (NT). Equal amounts (1 μg) were
incubated in loading buffer at 40 °C for 30 min, separated by a 4–20% tris-glycine
SDS-PAGE, and immunoblotted with 82E1 antibody. The position of 7.6- to 203-kDa
standards is shown, and a bracket indicates the heterogeneous high molecular weight
aggregates (H-agg). B. Relative integrated optical density of H-agg (circles) and ~8 kDa
(oligomer; triangles) bands were quantiﬁed and graphed. Best ﬁt non-linear regression
curves are one-phase exponential association and one-phase exponential decay,
respectively.
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studies have shown that similar centrifugation will pellet Aβ42 ﬁbrils
[39,40]. Samples taken before centrifugation (pre-spin) showed no
difference in H-agg staining as compared to supernatant (super) sam-
ples obtained after centrifugation (Fig. 3A). Dot blots indicated that
solutions pre-aggregated for 7 d and 30 d contained Aβ42 oligomers
whereas unaggregated samples (0 d) did not (Fig. 3B). Interestingly,
the 6E10 antibody immunostained pre-aggregated Aβ42 solutions
darker than unaggregated samples which may indicate conforma-
tion-dependent antibody recognition.
3.2. Assessment of Aβ42-induced synaptic decline in organotypic
hippocampal slice cultures
Organotypic hippocampal slice cultures were used for the sensi-
tive assessment of synaptic decline because they maintain native
neuronal organization and connections throughout the course of
long-term experiments [29]. Aβ42 was allowed to pre-aggregate for
5–7 d, at the two different temperatures, diluted to 300–500 nM in
serum free media, and applied daily to slice cultures for 7 consecutive104
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Fig. 3. Pre-aggregated Aβ42 solutions are not clariﬁed by low speed centrifugation and
contain oligomers. Aβ42 (45 μM in PBS) was allowed to aggregate for indicated time at
37 °C. A. Solutions were then centrifuged at 16,060×g for 25 min. Samples taken before
centrifugation (pre-spin) were compared with supernatant after centrifugation
(super) on a 16.5% tris-tricine SDS-PAGE, blotted onto nitrocellulose, and detected
with 82E1 antibody. B. Equal volume and amount of peptide (0.67 μg) was spotted
onto nitrocellulose, allowed to air dry, and detected with 6E10 antibody or A11 anti-
body. Peptides composed of a scrambled sequence of amino acids comprising Aβ42
(scram42) or the reverse sequence of Aβ42 (rev42) were allowed to aggregate for
7 d and also tested by dot blot as negative controls.days. Slices were harvested and protein aliquots were assessed by im-
munoblot for different glutamate receptor subunits. Aβ42 pre-aggre-
gated at 23 °C was more effective at compromising synaptic marker
expression, causing a decrease in AMPA receptor subunits GluR1
and GluR2 and NMDA receptor subunits NR1, NR2A and NR2B
(Fig. 4A). Compared to slices treated with vehicle, Aβ42 pre-aggregat-
ed at 23 °C reduced GluR1 by 69.8% (pb0.0001), whereas Aβ42 pre-
aggregated at 37 °C reduced GluR1 by only 22.7% (p=0.01; Fig. 4B).
Aβ42 pre-aggregated at 23 °C also decreased NR1 levels by 40.8%
(pb0.01) however the 37 °C solution had no affect on NR1 levels
compared to vehicle control (Fig. 4C). Immunohistochemical compar-
ison of slices treated with vehicle vs. Aβ42 pre-aggregated at 23 °C
revealed reduced GluR1 density in dendritic ﬁelds, especially in the
s. oriens, corresponding with a striking accumulation of GluR1 immu-
noreactivity in pyramidal neurons (Fig. 4D, F). This could be due to
transport blockage known to be produced by Aβ [41,42] and the re-
sultant buildup of the synaptic marker in the cell bodies causing
downregulation of its expression as found in the immunoblots. The
37 °C pre-aggregated Aβ42 solution also caused cellular GluR1 accu-
mulation and reduced dendritic staining (Fig. 4E), yet to a lesser ex-
tent than the 23 °C solution.
Next, the effect of pre-aggregated Aβ42 on presynaptic markers
was assessed as studies have shown a decrease in synaptophysin as-
sociated with AD [43,44]. Furthermore, a recent report found an
NMDA receptor-dependent decrease in synaptophysin by Aβ42, link-
ing pre- and postsynaptic markers through caspase cascades [45]. In
the present study, immunoblots showed a 58.8% decline in synapto-
physin by Aβ42 pre-aggregated at 23 °C (pb0.01) whereas Aβ42
pre-aggregated at 37 °C produced only a 24.2% decline compared to
vehicle (Fig. 5B). Other presynaptic markers synapsin IIA and IIB
also exhibited marginal declines in response to pre-aggregated
Aβ42 (Fig. 5A).
To test whether Aβ42-induced synaptic decline is aggregation-
dependent, hippocampal slices were treated with non-aggregated
or pre-aggregated Aβ42 solutions (Fig. 6A). As the immunoblot il-
lustrates, non-aggregated Aβ42 does not affect glutamate receptor
subunit levels, however, pre-aggregated Aβ42 signiﬁcantly reduces
GluR1 with respect to vehicle (pb0.0001) and reduces GluR1 by
65.6% as compared to non-aggregated Aβ42 (pb0.01; Fig. 6B).
Similarly, NR1 is signiﬁcantly reduced by pre-aggregated Aβ42
(pb0.05) but not by non-aggregated Aβ42 (Fig. 6C). Thus, Aβ42
affects synapses in an aggregation-dependent manner.
Since pre-aggregated Aβ42 solutions signiﬁcantly decreased glu-
tamate receptor subunits and presynaptic markers, Aβ42-induced
cell death was assessed in hippocampal slice cultures. Cultured slices
were treated for 7 d with vehicle or Aβ42 pre-aggregated at 23 °C, or
treated for 24 h with NMDA and AMPA as a positive control for exci-
totoxicity. Propidium iodide (PI) was used to stain cells with compro-
mised plasma membranes which is indicative of cell death (Fig. 7A, C,
E). The threshold of PI staining was determined using NMDA/AMPA
treated slices, and the area of PI staining in the CA1, CA3 and dentate
gyrus above threshold was measured (Fig. 7G, H; one-way ANOVA;
pb0.0001) as well as the ﬂuorescent optical density (Table 1). PI pos-
itive cells were observed in only 3 of the 10 Aβ42-treated slices and
were localized to the CA1 subﬁeld (Fig. 7C). Nissl stains were per-
formed to assess morphological changes and while pyknotic nuclei
were prevalent in the excitotoxic slices (Fig. 7F), little difference
was found between vehicle and Aβ42-treated slices (Fig. 7B, D).
Reduced vulnerability of synaptic markers corresponding with the
increased H-agg observed in the 37 °C pre-aggregated Aβ42 solutions
incited an investigation into the potency of 37 °C vs. 23 °C pre-aggre-
gated Aβ42 solutions. Hippocampal slice cultures were treated daily
for 7 consecutive days with indicated concentrations of Aβ42 aggre-
gated at either 37 °C or 23 °C. Slices were harvested and total protein
analyzed by immunoblot, assessing GluR1 levels as a sensitive marker
for synaptic decline (Fig. 8A). One-way analysis of variance indicated
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Fig. 4. Effects of pre-aggregated Aβ42 on glutamate receptor subunit levels in hippocampal slice cultures. Organotypic hippocampal slices were prepared and maintained in culture
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in GluR1 levels (pb0.0001). Two-way analysis of variance indicated
that both concentration and temperature of aggregation signiﬁcantly
affected GluR1 levels (pb0.0001). Treatment of hippocampal slices
with 80 nM Aβ42 aggregated at 37 °C showed little change of GluR1
levels compared to control (0 nM); however, 80 nM Aβ42 aggregated
at 23 °C caused a 38.2% decrease in GluR1 levels. At 300 nM, the 37 °C
solution induced only a 23.0% decrease in GluR1; however Aβ42 ag-
gregated at 23 °C reduced GluR1 levels by 69.8%. This trend was fur-
ther accentuated at higher doses as 600 nM of 37 °C pre-aggregated
solution decreased GluR1 by 42.1% whereas 23 °C pre-aggregatedsolutions caused a 90% reduction (Fig. 8B). In addition to synaptic de-
cline, Aβ42 pre-aggregated at 23 °C was found to induce cytoskeletal
compromise as indicated by detection of calpain-mediated spectrin
breakdown product (BDP; Fig. 8A). Allowing Aβ42 to oligomerize at
23 °C results in signiﬁcant synaptic decline in hippocampal slice cul-
tures; whereas pre-aggregation at 37 °C abates this effect.
3.3. Kinetics of Aβ42 aggregation
Since Aβ42 aggregate formation was shown to produce differen-
tial synaptic decline, we sought to better characterize the kinetics of
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of Aβ42 was incubated at 37 °C for 30 d, and aliquots were removed
over time, which were assessed by immunoblotting with 6E10. For-
mation of H-agg began at 3–4 h after the start of incubation and in-
creased in a time-dependent manner (Fig. 9A). In addition to the
increase in concentration of the H-agg species, as indicated by the
density of the band, the molecular weight exhibited an apparent in-
crease from 80 kDa at 0.1 d to nearly 100 kDa by 7 d. From the 0.1 d
time point, the dimeric species rapidly declined, whereas the mono-
meric species showed a more gradual decline throughout the time
course. Relative integrated optical band densities of the different spe-
cies were plotted and ﬁt to nonlinear regressions. The monomer and
dimer were found to model one-phase exponential decay curves
whereas H-agg modeled a one-phase exponential association curve
(Fig. 9B). Using this model, the half-life was estimated to be 1.54 d
for the dimer and 4.72 d for the monomer, and comparison of their
respective decay rates (K) indicated a signiﬁcant difference in the
rate of decay between the two species (pb0.0001; Table 2).
Given the increased potency of the Aβ42 solutions pre-aggregated
at 23 °C (Fig. 8), a comparison was made between Aβ42 solutions in-
cubated at 23 °C and 37 °C. Here, the same procedure as the previous
experiment was completed using aliquots of Aβ42 at each tempera-
ture. The immunoblot shows that Aβ42 incubated at either tempera-
ture begins to form H-agg within a few hours, and both samples show
an increase in H-agg band density and molecular weight over the
time course (Fig. 10). However, Aβ42 incubated at 37 °C shows a
much higher concentration of H-agg (compare band densities at 5 d
and 9 d) than Aβ incubated at 23 °C. Also, while the concentration
of the dimeric and monomeric species decreased slightly over the
time course in the 23 °C solution, the dimeric species is barely visibleby 9 d in the 37 °C solution. Band intensities were plotted over time
and as in Fig. 9B, one-phase exponential decay curves were used as
a model for the monomer (Fig. 10B) and dimer (Fig. 10C). The calcu-
lated half-life for the monomeric species and dimeric species at 23 °C
was 14.7 d and 8.45 d, respectively. There was no difference in the ex-
ponential decay rates between the monomer and dimer in the 23 °C
solutions; however, there was a signiﬁcant difference between the
exponential decay rate of the dimeric species upon comparison of
the 23 °C and 37 °C solutions (pb0.0001; Table 2). Also, a comparison
of the monomer/dimer ratio revealed a signiﬁcant difference between
the two solutions from 0.1 to 12 d (pb0.01; paired t-test; data not
shown).
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Fig. 7. Assessment of neurodegeneration induced by pre-aggregated Aβ42. Organotypic hippocampal slices were prepared and maintained in culture for 25 d. Aβ42 was pre-
aggregated at 23 °C for 5 d and diluted in serum free media to 500 nM. Hippocampal slices were treated with vehicle (A, B), or Aβ42 solution (C, D) daily for 7 d, and positive
controls were incubated with 100 μM NMDA and 100 μM AMPA for 24 h (E, F). Cultures were then incubated with media containing propidium iodide (PI), ﬁxed, mounted,
and subﬁelds imaged using epi-ﬂuorescence (A, C, E), followed by Nissl staining and imaging of the CA1 subregion under brightﬁeld (B, D, F). Means±SEM of image area pos-
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ANOVA (Kruskal–Wallis test) indicated a signiﬁcant difference of PI-positive area across the hippocampal subﬁelds of Aβ42-treated slices (pb0.05). DG, dentate gyrus; so,
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Table 1
Mean PI ﬂuorescent optical densities (sum density)±SEM after vehicle, Aβ42, or
100 μM each NMDA/AMPA treatment in hippocampal slice cultures.
Vehicle, 7 d Aβ42, 7 d NMDA/AMPA, 24 h
CA1 1.42±1.41 24.3±16.1 21122±15622
CA3 3.30±3.30 0±0 370±308
DG 0±0 0±0 504±500
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This study explores the propensity of soluble Aβ42 to aggregate,
and the extent to which aggregation is time and temperature depen-
dent. The heterogeneous Aβ42 aggregate solutions were evaluated
for their ability to reduce the expression of glutamate receptor sub-
units and presynaptic markers in hippocampal slice cultures. Incubat-
ing Aβ42 solutions at 23 °C or 37 °C promoted the formation of high
molecular weight aggregates at the expense of dimeric and mono-
meric species. However, formation of high molecular weight aggre-
gates occurs more quickly and to a greater extent at 37 °C compared
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Fig. 8. Synaptic compromise potency proﬁle for the different Aβ42 preparations in hip-
pocampal slice cultures. Aβ42 was pre-aggregated in PBS, diluted to the indicated con-
centration with serum free media, and applied to hippocampal slices. After 7 daily
treatments with vehicle control or Aβ42 solutions, the cultured slices were harvested,
sonicated, and equal protein immunoblotted for GluR1 and calpain-mediated spectrin
breakdown product (BDP). A. Representative immunoblot from hippocampal slice
samples treated with vehicle control or different concentrations of Aβ42 pre-aggregated
at 23 °C. B. Mean integrated optical densities±SEM of GluR1 immunoreactivity from
hippocampal slices treated with Aβ42 pre-aggregated at 37 °C (open squares) or 23 °C
(ﬁlled squares) are plotted. One-way ANOVA: pb0.0001, Aβ42 pre-aggregated at 23 °C;
N.S., Aβ42 pre-aggregated at 37 °C. Two-way ANOVA: pb0.0001, n=4–12. Bonferroni's
post-tests: **pb0.01 and ***pb0.001.
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Fig. 9. Time-dependent formation of Aβ42 high molecular weight aggregates at 37 °C.
Aβ42 at 45 μM in PBS was aggregated for the indicated number of days at 37 °C or pre-
pared from fresh stock (NT). Aliquots of peptide (1 μg) were mixed with loading buffer,
incubated 30 min at 40 °C, run on 16.5% tris-tricine SDS-PAGE, and immunoblotted for
Aβ. A. The 6E10 antibody labeled monomer and dimer species (arrows), as well as high
molecular weight aggregates (H-agg). Positions of 4.0- to 104-kDa standards are
shown. B. Relative integrated optical densities of bands corresponding to monomer
(inverted open triangle), dimer (ﬁlled triangle), and high molecular weight aggregates
(ﬁlled circle) were plotted. The best ﬁt nonlinear regressions were curves for one-
phase exponential decay (monomer and dimer) and one-phase exponential associa-
tion (H-agg).
Table 2
Decay rate (K)±SEM of Aβ42 species.
Incubation temperature 23 °C 37 °C 23 °C vs. 37 °C
Monomer K=0.047±0.052 K=0.147±0.038 N.S.
Dimer K=0.082±0.016 K=0.451±0.037 pb0.0001
Monomer vs. dimer N.S. pb0.0001
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exhibited by the dimer at 37 °C; the temperature that promotes high
molecular weight aggregate formation. Thus, dimers are likely to play
a signiﬁcant role in the formation of high molecular weight aggre-
gates. Related to our ﬁndings is previous work in which modiﬁed
Aβ40 dimers seeded higher order aggregates much more readily
than Aβ40 monomers [46]. This potentially explains the signiﬁcantly
faster decay rate of the dimeric species at 37 °C.
Incubating long-term hippocampal slice cultures with the pre-
aggregated Aβ42 solutions was found to cause sequelae of synaptic
compromise, whereas non-aggregated Aβ42 solutions at the submi-
cromolar concentrations tested had no effect on synaptic markers.
GluR1 and NR1 levels decreased in response to Aβ42 pre-aggregated
at 23 °C, with GluR1 declining by concentrations as low as 80 nM.
Other subunits of the excitatory amino acid receptors, GluR2,
NR2A, and NR2B, followed the same trend, declining in response to
Aβ2 pre-aggregated at 23 °C. Perhaps overactivation of the AMPA
and NMDA receptors by Aβ42 leads to downregulated expression
of their subunits and disruption of synaptic signaling. In recent stud-
ies, nanomolar levels of Aβ oligomers present in the AD brain were
reported to increase NMDA receptor activation and thereby impair
synaptic plasticity [47,48]. NR2B-containing NMDA receptors were
the focus of the two studies and such receptors have been proposed
to play a particularly important role in excitotoxicity. Evidence of
overactivated excitatory receptors in the current study is indicatedby the detection of calpain-mediated spectrin breakdown product,
a sensitive marker of excitotoxic events and early stage neuronal de-
generation [29,49].
Both AMPA and NMDA signaling affect long-term potentiation
(LTP), which is widely viewed as a model for memory formation and a
measure of synaptic plasticity (review in [50]). Glutamatergic signaling
through both the NMDA and AMPA receptors is signiﬁcantly affected in
the AD brain [51], and the degree of cognitive impairment demon-
strated by patients with AD strongly correlates with synaptic decline
[52–54]. The data presented here corroborate previous work that has
shown a decrease in both GluR1 levels and surface expression of
NMDA receptors in cultured neurons isolated from transgenic mouse
models of AD [27,55]. Also, aggregated Aβ42, but not Aβ40, inhibits
the ability of CA1 hippocampal pyramidal neurons to signal through
AMPA receptors [26], and it induces endocytosis of NMDA receptors in
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Fig. 10. Comparison of time-dependent Aβ42 aggregation at 23 °C vs. 37 °C. Aβ42 in
PBS was aggregated at 23 °C or 37 °C for the indicated times or prepared from fresh
stock (NT). Aliquots of 1 μg peptide were mixed with loading buffer, incubated
30 min at 40 °C, separated on 16.5% tris-tricine SDS-PAGE, and immunoblotted with
the 6E10 antibody. A. Molecular weight standards from 4.0 to 104 kDa are indicated;
arrows show monomeric and dimeric species and bracket indicates high molecular
weight aggregates. B–C. Relative integrated optical densities of bands corresponding
to monomer (B) and dimer (C) were compared for solutions incubated at 23 °C
(squares) and 37 °C (triangles). The best ﬁt nonlinear regression curve (one-phase
exponential decay) for each is illustrated.
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are of continued interest due to recent ﬁndings indicating that not
only does Aβ inﬂuence NMDA receptors, but NMDA responses can
both elevate synaptic Aβ generation and reduce APP processing into
Aβ depending on the level of signaling intensity [56]. Physiological con-
centrations of naturally-secreted Aβ dimers and trimers have also been
shown to require the activity of NMDA receptors to mediate spine loss
in organotypic cultures [57]. In addition to glutamate receptor subunitdecline, Aβ42 pre-aggregated at 23 °C induced a signiﬁcant decline in
synaptophysin, further conﬁrming the early synaptotoxic effects of
this preparation. Collectively, these results indicate that pre-aggregated
Aβ42 has the ability to induce the synaptic decline that is characteristic
of AD-type pathogenesis. Despite the detrimental effect on synaptic in-
tegrity, aggregated Aβ42 induced limited cellular degeneration thatwas
localized to CA1. This may be related to the fact that exogenous Aβ42
uptake is speciﬁc to pyramidal neurons in CA1 [30], and this study con-
ﬁrms the susceptibility of this region to aggregated Aβ42. We believe
that the 7 d treatment with submicromolar concentration of Aβ42
that resulted in synaptic decline may not be long enough for overt neu-
ronal degeneration to be observed in the hippocampal slice model.
Interestingly, pre-aggregated Aβ42 solutions containing higher
concentrations of H-agg are less capable of reducing synaptic pro-
teins. This indicates that high molecular weight Aβ aggregates may
be protective through sequestration of synaptotoxic oligomers. AD-
associated cognitive decline was initially attributed to amyloid pla-
ques [58–61]; however, it was later discovered that neurodegenera-
tion more closely correlates with soluble Aβ levels [17,18]. Much
effort has been placed into identifying the form of Aβ that is neuro-
toxic. Interestingly, the data presented here indicate that an increased
rate of decay of Aβ42 dimers in favor of higher molecular weight ag-
gregate formation corresponds with decreased neuronal compromise.
This supports the growing number of studies that implicate low mo-
lecular weight oligomers, especially Aβ42 dimers and trimers, as
the primary neurotoxic species [21,62,57,63]. Together, the ﬁndings
substantiate that high molecular weight Aβ42 complexes have the
potential to sequester toxic oligomeric species, thereby lowering
their concentration below the threshold for synaptotoxic effects. A re-
cent study in C. elegans showed that experimental induction of amy-
loid deposits leads to decreased levels of Aβ oligomers and
protection against neuromuscular synaptic defects [64]. We also
found that the Aβ42 dimer decays faster than the monomeric species
in the less toxic solutions pre-aggregated at 37 °C. Thus, as an alterna-
tive hypothesis, since monomers have been shown to be neuropro-
tective [65], is that the difference in the monomer/dimer ratio could
play a role in promoting or suppressing synaptotoxicity.
Therapeutic strategies have been targeted at disaggregation of
Aβ, either extracellularly or intracellularly, to facilitate lysosomal
degradation and promote cellular uptake of the peptide for trafﬁcking
to lysosomes [66]. The present study suggests extracellular pro-
aggregation of Aβ oligomers as a self-repair mechanism in the brain
and as a novel therapeutic avenue. We have shown that aggregation
of Aβ42 is time- and temperature-dependent, species of Aβ oligomers
are differentially affected by temperature, and that this affects the
synaptotoxic properties of Aβ. The tendency of Aβ42 to form high mo-
lecular weight species and the dimers being the ﬁrst pool of lowmolec-
ular weight species to be correspondingly depleted has important
implications for the treatment of AD. If the high molecular weight com-
plexes are indeednontoxic, increasing the rate of highmolecularweight
aggregate formation may in fact reduce low molecular weight oligo-
mers that are responsible for synaptic degeneration and thus cognitive
decline.
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